Clinical Laboratory Services Introduce Diagnosis of Invasive Fungal Infections

This problem is exacerbated by the growing numbers of patients at risk, including transplant patients and those undergoing immunosuppressive therapy or immunocompromised due to human immunodeficiency virus (HIV) infection. Immunetics, Inc. (Boston, MA, USA) a leading developer of clinical diagnostic assays, announced the launch of its new MycoDx assay for invasive fungal infections, which will be offered through its clinical reference laboratory service.

MycoDx is a multiplex molecular assay that can identify 21 fungal pathogens in a whole blood sample. Clinical samples can be tested directly with MycoDx, eliminating the prior culturing step required by many other assays. This capability reduces assay turnaround time, providing earlier results to clinicians to enable more effective treatment of life-threatening fungal infections. Such infections are particularly dangerous to immunocompromised patients including transplant recipients and those undergoing cancer therapies.

The assay results for a panel of 21 fungal targets including Candida, Aspergillus, Cryptococcus, Coccidioides, Fusarium and other species. Additional fungal targets are currently under development. Results are directly from whole blood patient samples as no blood cultures are required. Additional sample types are currently under development. There is a rapid assay turnaround time of 8 hours for all 21 targets, while most current methods can take 48 to 72 hours or more.

John Yonkin, CEO of Immunetics, said, “Our development team is currently working to transfer the assay into a user friendly microarray format for worldwide distribution. This will truly be transformational for the diagnosis of fungal disease, offering every hospital and reference laboratory access to unique technology to detect a broad range of fungal targets with same-day results.”

Related Links:
Immunetics, Inc.